These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34643917)

  • 1. Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.
    Iacobellis G; Baroni MG
    J Endocrinol Invest; 2022 Mar; 45(3):489-495. PubMed ID: 34643917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
    Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy.
    Iacobellis G; Basilico S; Malavazos AE
    Handb Exp Pharmacol; 2022; 274():93-108. PubMed ID: 35156138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk.
    Marx N; Grant PJ; Cosentino F
    Eur Heart J; 2020 Jan; 41(2):329-330. PubMed ID: 31800036
    [No Abstract]   [Full Text] [Related]  

  • 5. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epicardial fat: a new cardiovascular therapeutic target.
    Iacobellis G
    Curr Opin Pharmacol; 2016 Apr; 27():13-8. PubMed ID: 26848943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epicardial fat links obesity to cardiovascular diseases.
    Iacobellis G
    Prog Cardiovasc Dis; 2023; 78():27-33. PubMed ID: 37105279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
    Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
    Brown E; Wilding JPH; Barber TM; Alam U; Cuthbertson DJ
    Obes Rev; 2019 Jun; 20(6):816-828. PubMed ID: 30972878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease.
    Bakkar NZ; AlZaim I; El-Yazbi AF
    Clin Sci (Lond); 2022 Nov; 136(22):1631-1651. PubMed ID: 36383188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.
    Khat DZ; Husain M
    Curr Diab Rep; 2018 Jun; 18(7):45. PubMed ID: 29886514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes.
    González N; Moreno-Villegas Z; González-Bris A; Egido J; Lorenzo Ó
    Cardiovasc Diabetol; 2017 Apr; 16(1):44. PubMed ID: 28376896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.
    DeFronzo RA
    Diabetes Obes Metab; 2017 Oct; 19(10):1353-1362. PubMed ID: 28432726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials.
    Costantino S; Paneni F
    Vascul Pharmacol; 2019 Apr; 115():64-68. PubMed ID: 30926561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.